Key statistics
As of last trade Apellis Pharmaceuticals Inc (1JK:MUN) traded at 25.31, 0.44% above its 52-week low of 25.20, set on Oct 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.31 |
---|---|
High | 25.31 |
Low | 25.31 |
Bid | 24.95 |
Offer | 25.44 |
Previous close | 25.62 |
Average volume | 333.50 |
---|---|
Shares outstanding | 121.77m |
Free float | 104.38m |
P/E (TTM) | -- |
Market cap | 3.35bn USD |
EPS (TTM) | -2.74 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 07:01 BST.
More ▼
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
- Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
- Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
- Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
- SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
More ▼